We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement
Analytical Cannabis Logo
×

Cannabis Policy

Medical Cannabis Users Could Still be Criminalised in UK Despite Government Accepting its Benefits

Under current recommendations, people who use cannabis for conditions including chronic pain, arthritis, the side effects of chemotherapy and even the self-medication of brain and other tumours, will continue to be criminalised.

Read More

Torts and Courts: How the Cannabis Industry Can Protect Itself from Legal Action

The cannabis industry has largely escaped negligence cases to date, mainly due to legal uncertainties - experts claim this ‘tort cease-fire’ is coming to an end.

Read More

Crime Clearance Rates Positively Impacted by Cannabis Legalization

In Colorado and Washington arrest rates for cannabis has fallen and crime clearance rates for violent crime, burglary, motor vehicle theft and property crime have shifted upward.

Read More

Multiple Case Studies Show Potential Danger of Cannabis Contaminants

Preventive steps and remediative action are required to reduce the prevalence of contamination from microbes, heavy metals and, pesticides.

Read More

CBD Market Set to Grow as Regulatory Change Looms in U.S.

The market for cannabis and hemp products has seen a low-key but potentially huge step forward in recent weeks.

Read More

A Big Step Forward for Medical Marijuana

Medical marijuana has picked up considerable momentum after a U.S. FDA advisory panel unanimously recommended approval of GW Pharmaceuticals' epilepsy medication, Epidolex.

Read More

Medical Cannabis and the Challenge for Regulation of Medicines

Reviews of scientific evidence show promising findings for some, but not all, conditions for which cannabis is considered a treatment – and this evidence is difficult to untangle.

Read More

Advancing Cannabinoid Research in Australia

Pioneering researchers are developing cannabinoid formulations to help doctors and patients control their dosing, as well as help researchers better study the drug in clinical trials.

Read More

Monopoly on FDA-approved Cannabis May Hold Back Parkinson's Drug Development

GB Sciences are looking for international suppliers that produce minor cannabinoids and terpenes to ensure that it can expand testing beyond their planned, initial Phase 0 Trial.

Read More

 
Advertisement